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INTRODUCTION
INTRODUCTION
In response to a traumatic brain injury or physiological “insult” to
the brain (e.g., hemorrhagic or ischemic stroke), some patients suffer
global and irreversible loss of brain stem function, leading to a diagnosis
of brain death. Some of these patients may be candidates for organ and
tissue donation, a decision mediated by the patient’s previously
expressed wishes, sometimes in the form of an advance directive or
organ donor card, and the preferences of the patient’s family. Patients
with irreversible brainstem dysfunction are potential candidates for
organ donation. As the awareness regarding organ donation and the
frequency of donation are increasing with time, organ preservation
strategies and protocols should be followed meticulously to improve the
outcome of donation programme.
After the diagnosis of brain death the focus of patient care shifts
from interventions aimed at saving the patients (donor) life to
interventions aimed at maintaining viability of potentially transplantable
organs.
As  the  brainstem  dysfunction  evolves  the  there  occurs  so  many
alterations in the normal physiology. The resultant changes in the cell
2homeostasis can adversely affect the donor organ viability which in turn
affect the graft function.
By understanding the pathophysiology of brain death we can
manage the adverse changes reasonably, which may improve the
survival of the grafted organs.
Among the major changes endocrine changes are worth
mentioning. Diabetes insipidus is the most common endocrine
abnormality seen in the brain-dead patients, manifests earlier or later
during the process(1)(2).
One of the effects of diabetes insipidus is hypernatremia, defined
as serum sodium level >145mEq/L(3).
 Organs commonly harvested are kidneys, liver, heart/heart
valves, cornea etc. Donor organs affected by hypernatremia are liver,
kidneys, heart. Of these liver grafts are more prone to early rejection.
Effects are more when the sodium levels are > 155mEq/L particularly
when it is a persistent one for longer duration before procurement(3).
3Various studies have showed the relationship between the serum
sodium level and the graft survival and explained the adverse effects of
hypernatremia.
So managing the hypernatremia can improve the survival of
transplanted organs especially the liver. Which is the theme of this
study.
There are many approaches for managing the hypernatremia.
Among them I have chosen the exogenous vasopressin administration to
replace the reduced serum vasopressin level as the treatment of choice
because it also has potent vasopressor property which will be useful in
maintaining hemodynamic stability in these patients due to the
frequently accompanying autonomic failure.
Other derangements also have to be corrected with fluid
replacement, dopamine, thyroxine, methyl prednisolone, insulin-KCL
regimen, antibiotics etc.
 In this study I have attempted to evaluate the role of vasopressin
in the management of hypernatremia in clinically brain-dead patients, by
comparing the serum sodium levels before and after initiating the
vasopressin infusion therapy.
BRAINDEATH
AND
HYPERNATREMIA
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BRAINDEATH
Definition:
Irreversible cessation of all functions of the entire brain, including
the brain stem.
Causes:
? Severe head trauma
? Aneurysmal subarachnoid hemorrhage
? Cerebro vascular injury
? Hypoxic-ischemic encephalopathy
? Fulminant hepatic necrosis
? Prolonged cardiac resuscitation or asphyxia
? Tumors.
Pathophysiology:
MECHANISM
Following any major injury there will be
(1) Ischemia and (2) Re-perfusion injury (later).
5High-energy stores are depleted, Ca2+ influx overwhelms the
ionic pumps, endothelial swelling develops and reactive oxygen species
accumulate secondary to insufficient perfusion.
Activation of inflammatory mediators such as the complement
system, thromboxanes, platelet and leukocyte factors are central to the
pathophysiologic events after onset of brain death. As time progresses,
there is a progressive leukocyte influx into solid organs with a
continuous inflammatory deterioration that enhances the
immunogenicity of the graft. There is ameasurable increase of
inflammatory compounds: intercellular adhesion molecule-1 (ICAM-1),
vascularcellular adhesion molecule-1 (VCAM-1), E-selectin,
interleukin-6, interferon-G, macrophage inflammatory protein-1?,
tumour necrosis factor-? and countless others(4).
Major physiologic changes:
Loss of brain stem function results in systemic physiologic
instability:
- Initial catecholamine storm followed by depletion (autonomic
failure) ? CVS instability, arrhythmias, hypertension
followed by hypotension.
6- Loss of vasomotor control (Hypothalamus damage) leads to a
hyperdynamic state.
- Loss of respiratory function- apnoea, impaired gas exchange
- Loss of temperature regulation (Hypothalamus damage) ?
Hypothermia
- Endocrine failure due to Hypothalamus & pituitary damage ?
DI, hypothyroid, steroid depletion, insulin resistance-
intravascular volume depletion, electrolyte imbalance
(hypernatremia), hyperglycemia etc(5).
Incidence of major pathophysiological changes:
  -  Hypotension 81%
- Diabetes Insipidus 72-77%
 - DIC 28%
 - Cardiac arrhythmias 25%
 - Pulmonary edema 18%
 - Metabolic acidosis 11%
7Normal brain functions
Part of brain Normal function Brain death
CEREBRUM Cognition, Voluntary
movements, Sensation
Coma
BRAINSTEM Cranial nerve nuclei,
Respiration
Absent brainstem
reflexes , Apnea
RAS Wakefulness Coma
Brain-Death Criteria:
? Absent Cerebral Function(coma)
? Absent Brainstem reflexes
? Apnea- Once coma and absence of brain stem reflexes have
been confirmed?Apnea test.
- Verifies loss of most rostral brain stem function
- Confirmed by PaCO2 > 55 mmHg or PaCO2 >15 mmHg
over baseline value during apnea period-with no
respiratory attempt
- 2 tests at 6 hrs interval
8In paediatric age group
? Clinical examination is same as in adults.
? Testing criteria depends on age of child.
- Neonate < 7 days? Brain death testing is not valid.
- 7 days – 2 months
? Two clinical exams and two EEG 48 hrs apart.
- 2 months – 1 year
? Two clinical exams and two EEG 24 hrs apart.
? or two clinical exams, EEG and blood flow study.
- Age > 1 year to 18 years
? Two clinical exams 12 hrs apart, confirmatory  study -
Optional
Confirmatory tests
? Cerebral Blood Flow (CBF) Studies
? Cerebral Angiography
? Nuclear Flow Study
? EEG (when brain scan is not utilized)
9? Other rarely used tests
- Transcranial doppler ultrasonogram
- Spiral computer tomogram
- Magnetic resonance imaging(6)
Confirmatory tests are,
? Purely optional when the clinical criteria are met
unambiguously.
? A confirmatory test is needed for patients in whom specific
components of clinical testing cannot be reliably evaluated
- Incomplete brain stem reflex testing
- Incomplete apnea testing
- Toxic drug levels
- Children younger than 1 year old.
- Required by institutional policy
DIABETES INSIPIDUS
? Diabetes insipidus can be defined as urine ouptut >4 mL/kg
per hr in adults and children
? Associated with rising serum sodium (? 145 mmol/L)
? Associated with rising serum osmolarity (? 300 mosM) and
decreasing urine osmolarity (? 200 mosM)(3).
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HYPERNATREMIA
? It is defined as serum sodium level > 145meq/L
? Causes of hypernatremia in braindead patients
- ADH(Vasopressin) deficiency secondary to posterior
pituitary infarction(central diabetes incipidus) -which
results in increased free water clearance.
- Sodium overload (NS)
- Rarely nephrogenic DI
Adverse effects of hypernatremia on donor organs
? Donor hypernatremia with serum sodium levels > 155meq/L
has been reported to be associated poorer liver graft outcome
in comparison with normonatremicdonors(3).
? Due to the formation idiogenicosmoles in donor hepatocytes to
maintain IC osmolarity to avoid cellular dehydration.
? Donor hypernatremia also associated with renal and cardiac
graft dysfunction.
11
Hypernatremia
? Results in early graft loss
? Affects patient survival
? Prolongs ICU stay
? Elevated liver enzymes in the post-op period
Duration of hypernatremia also influences the graft survival.
SO, MANAGING THE SERUM SODIUM LEVEL WITHIN
NORMAL LIMITS MAY IMPROVE GRAFT SURVIVAL
(ESPCIALLY LIVER).
Management of hypernatremia in brain-dead patients:
Hyperglycemia, cold diuresis, preceding diuretic treatment for
cerebral edema, the diuretic effect of radiographic contrast material used
for angiography or the diuretic reaction to an iatrogenic overhydration
should be excluded before treatment with vasopressin is commenced.
Serum sodium target range is 130–150 mmol/L.
1. Vasopressin infusion - dose – 0.5 to 3U/hr (or) 0.01 to 0.04
U/min(10-40mU /kg/hr)
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- max. safety dose without much CVS compromise 0.04U/min
or 40mU/kg/hr
- 1U i.v bolus can be given before infusion
The pediatric dose range for vasopressin is 0.0003–0.0007 U/kg
per minute (0.3–0.7 mU/kg per minute) to a maximum dose of 2.4
U/h.(3)
2.  Desmopressin-  adults:  1–4  ?g  IV  then  1–2  ?g  IV  every  6  h  to
achieve urine output < 4 mL/kg/h.(7)
Children : 0.25–1 ?g IV every 6 h to achieve urine output
<4mL/kg/h.
Intranasal10 – 40 mics in 2-3 divdeddoses.
DDAVP  is  an  analog  of  AVP  with  a  relatively  pure  antidiuretic
effect and negligible vasopressor activity. Upper limits of DDAVP
dosing are empirical. There is no clear upper limit for DDAVP dose, as
it should be titrated to achieve the desired effect of reducing urine
output.
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Under the following circumstances, vasopressin infusion should
be the first choice:
1. Hemodynamic support with vasospressin required
2. Combination hormonal therapy implemented(8)
3. Avoiding sodium cotaining fluids
4. Use fluids with high free water
Hemodynamic Instability
Hemodynamic instability following brain death can be attributed
to three main causes. First, a sympathetic surge immediately preceding
medullary level brain death leads to a massive release of catecholamines
from postganglionic sympathetic nerve endings leading to elevated
systemic vascular resistance, hypertension, left ventricular dysfunction,
cardiac stunning, neurogenic pulmonary edema, and arrhythmias.
Second, herniation following brain death leads to spinal cord infarction
and loss of sympathetic tone resulting in further hypotension. Third,
pituitary hormonal secretion ceases and the body enters a
panhypopituitary state characterized by low cortisol, T3, T4, insulin, and
ADH levels. Ensuing diabetes insipitus leads to further hypotension as
the patient becomes volume depleted.
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Management of other alterations in brain-dead patients
1. Hypotesion
? Maintain CVP at 12-15mmHg with fluids
? Inotropes (dopamine, dobutamine)
? Vasopressors(vasopressin)
2. Combined hormonal therapy is defined as administration of
? Thyroid hormone (tetraiodothyronine or T4), 20 ?g IV bolus
followed by 10 ?g/h IV infusion
? Vasopressin, 1 U IV bolus followed by 2.4 U/h IV infusion
? Methylprednisolone, 15 mg/kg IV every 24 h.
? Insulin infusion based on hourly blood sugar.
It is recommended in donors with an ejection fraction ? 40%,
basedon 2-dimensional echo cardiographic assessment, or hemodynamic
instability. Consideration should be given to its use in all donors.
3. Tansfusion threshold:
A target hemoglobin level of 90–100 g/L is most appropriate to
optimize cardiopulmonary function in the face of hemodynamic
15
instability.  A  level  of  70  g/L  is  the  lowest  acceptable  limit  for
management of stable donors in the ICU.
? There are no defined targets for platelet concentration,
international normalized ratio or partial thromboplastin time.
Platelet or plasma factor replacement is indicated for clinical
bleeding only.
? Blood drawing for donor serology and tissue typing should
occur before transfusions to minimize the risk of false results
related to hemodilution.
? No special transfusion precautions are required in organ
donors.
4. Antibiotics
An initial baseline blood culture should be carried out for all
donors and repeated after 24 h and on an as-needed basis.
? Positive blood cultures or confirmed infections are not
contraindications to organ donation.
? Antibiotic therapy should be initiated in cases of proven or
presumed infection. Duration of therapy depends on the
16
virulence of the organism and decisions should be made in
consultation with the transplant team and infectious disease
services.
? No minimum duration of therapy before organ procurement
can be defined at this time.
5. Oxygenation & ventilation
Mechanical ventilation with the following targets:
? fraction of inspired oxygen (Fio2) titrated to keep oxygen
saturation ? 95% and partial pressure of arterial oxygen (PaO2)
? 80 mm Hg
? pH: 7.35–7.45, PaCO2: 35–45 mm Hg
? Positive end expiratory pressure (PEEP): 5 cm H2O.
6. Glycemic control
Glucose control with insulin infusions titrated to achieve a blood
glucose level of 4–8 mmol/L is recommended.
VASOPRESSIN
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VASOPRESSIN
? An Amino peptide
? Vasopressin Chemical Structure
? The antidiuretic mechanism involves two anatomical
components: a CNS component for the synthesis, transport,
storage, and release of vasopressin and a renal collecting-duct
system composed of epithelial cells that respond to vasopressin by
increasing their permeability to water.(8)
? Synthesis- Hypothalamus-Supra-optic nuclei, Paraventricular
nuclei (magno cellular neurons)
18
PITUITARY GLAND
HYPOTHALAMIC NUCLEI
Vasopressin synthesis appears to be regulated solely at the
transcriptional level. In human beings, a 168-amino acid
19
preprohormoneis synthesized. During synthesis, the signal peptide is
removed to form the vasopressin prohormone, which then is processed
and incorporated into the Golgi compartment. The synthesis and
transport of vasopressin depend on the conformation of the
preprohormone. In particular, VP-neurophysin binds vasopressin and is
critical to the correct processing, transport, and storage of vasopressin.
Genetic mutations in either the signal peptide or VP-neurophysin give
rise to central diabetes insipidus.
Storage- Posterior pituitary.The long axons of magnocellular
neurons in the SON and PVN transverse the external zone of the median
eminence to terminate in the neural lobe of the posterior pituitary
(neurohypophysis), where they release vasopressin and oxytocin.-
Stimulus
1. Serum Hyperosmolality
The osmolality threshold for secretion is approximately 280
mOsm/kg. Below the threshold, vasopressin is barely detectable in
plasma, and above the threshold, vasopressin levels are a steep and
relatively linear function of plasma osmolality. A small increase in
plasma osmolality leads to enhanced vasopressin secretion. Indeed, a
20
2% elevation in plasma osmolality causes a two- to threefold increase in
plasma vasopressin levels, which, in turn, causes increased solute-free
water reabsorption, with an increase in urine osmolality. Increases in
plasma osmolality above 290 mOsm/kg lead to an intense desire for
water (thirst). It is important to point out, however, that above a plasma
osmolality of approximately 290 mOsm/kg, plasma levels of
vasopressin exceed 5 pM. Since urinary concentration is maximal (about
1200 mOsm/kg) when vasopressin levels exceed 5 pM, further defense
against hypertonicity depends entirely on water intake rather than on
decreases in water loss.
Several CNS structures are involved in osmotic stimulation of
vasopressin release by the posterior pituitary; these structures are
collectively referred to as the osmoreceptive complex. Although
magnocellular neurons in the SON and PVN are osmosensitive, afferent
inputs from other components of the osmoreceptive complex are
required for a normal vasopressin response.
The SON and PVN receive projections from the subfornical organ
(SFO)  and  the  organumvasculosum  of  the  lamina  terminalis  (OVLT)
either directly or indirectly via the median preoptic nucleus (MnPO).
Subgroups of neurons in the SFO, OVLT, and MnPO are either
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osmoreceptors or osmoresponders (i.e., are stimulated by osmoreceptive
neurons located at other sites). Thus a web of interconnecting neurons
contributes to osmotically induced vasopressin secretion. Aquaporin 4, a
water-selective channel, is associated with CNS structures involved in
osmoregulation and may confer osmosensitivity. In the CNS, aquaporin
4 resides on glial and ependymal cells rather than on neurons,
suggesting that osmotic status may be communicated to the neuronal
cell by a glial-neuron interaction.
2. Hypovolemia and Hypotension
Vasopressin secretion also is regulated hemodynamically by
changes in effective blood volume and/or arterial blood pressure.
The neuronal pathways that mediate hemodynamic regulation of
vasopressin release are different from those involved in osmoregulation.
Baroreceptors in the left atrium, left ventricle, and pulmonary veins
sense blood volume (filling pressures), and baroreceptors in the carotid
sinus and aorta monitor arterial blood pressure. Nerve impulses reach
brainstem nuclei predominantly through the vagal trunk and
glossopharyngeal nerve; these signals are relayed to the solitary tract
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nucleus, then to the A1-noradrenergic cell group in the caudal
ventrolateral medulla, and finally to the SON and PVN.
3. Endogenous agents
Several agents are known to stimulate vasopressin secretion,
including acetylcholine (via nicotinic receptors), histamine (via H1
receptors), dopamine (via both D1 and  D2 receptors), glutamine,
aspartate, cholecystokinin, neuropeptide Y, substance P, vasoactive
intestinal polypeptide, prostaglandins, and angiotensin II. Inhibitors of
vasopressin secretion include atrial natriuretic peptide, g-aminobutyric
acid, and opioids (particularly dynorphinvia k receptors).
4. Drugs
Stimulators of vasopressin secretion include vincristine,
cyclophosphamide, tricyclic antidepressants, nicotine, epinephrine, and
high doses of morphine. Lithium, which inhibits the renal effects of
vasopressin, also enhances vasopressin secretion. Inhibitors of
vasopressin secretion include ethanol, phenytoin, low doses of
morphine, glucocorticoids, fluphenazine, haloperidol, promethazine,
oxilorphan, and butorphanol. Carbamazepine has a renal action to
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produce antidiuresis in patients with central diabetes insipidus but
actually inhibits vasopressin secretion via a central action.
Receptors and mechanism
Type
Second
Messenger
Site Effect
V1 G1q-PLC,
IP3, DAG
Vascular
smooth muscle
Vasoconstriction
V2 AC-cAMP CD of renal
tubule
Anti-diuresis, viii &
vwf release
V3 PLC, IP3,
DAG
CNS ACTH release
Pharmacological effects
V1-receptor-mediated therapeutic applications are based on the
rationale that V1 receptors cause contraction of gastrointestinal and
vascular smooth muscle.
V2-receptor-mediated therapeutic applications are based on the
rationale that V2 receptors cause water conservation and release of blood
coagulation factors. Central but not nephrogenic DI can be treated with
V2-receptor agonists, and polyuria and polydipsia usually are well
controlled. Some patients experience transient DI (e.g., in head injury or
24
surgery in the area of the pituitary); however, therapy for most patients
with DI is lifelong.
? CVS- Vasoconstriction-skin, skeletal muscle, fat-GIT,
coronary, brain.
Despite the potency of vasopressin as a direct vasoconstrictor,
vasopressin-induced pressor responses in vivo are minimal and
occur only with vasopressin concentrations significantly higher than
those required for maximal antidiuresis.
? RENAL- Aquaporin2 mediated increased water permeability
in principal cells of collecting tubules. (water & electrolyte
balance)
? CNS- ACTH release
? COAGULATION- Release of factor viii & Vwf from
endothelium- HEMOSTASIS.
? OTHERS- smooth muscle contraction in GIT & uterus,
platelet aggregation, glycogenolysis etc.
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Diseases affecting vasopressin system
When <5pg/ml, linear decrease in body’s ability to maximally
concentrate urine and when it is <1pg/ml urine volume increases
dramatically from <4L to >20L/day.
1. Diabetesinsipidus - central/neurogenic, nephrogenic - reduced
vasopressin level or function.
2. Syndrome of Inapproprite ADH secretion-excess serum
vasopressin levels
Synthetic analogues
? Synthetic vasopressin- nanopeptide
? Pharmacokinetics – Vasopressin
- t 1/2- 17 to 35 mins
- duraion – 2 to 8 hrs
- if given orally – digested by trypsin
? Desmopressin – potent V2 receptor agonist.
It has enhanced antidiuretic potency, greatly diminished pressor
activity and prolonged half-life as compared to Vasopressin.
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- t 1/2, - Fast component-6.5 to 9 mins
- Slow component-30 to 117mins
? Other Vasopressin analogues/V1 receptor agonists-e.g.
terlipressin
Therapeutic uses
Two antidiuretic peptides are available for clinical use.
Vasopressin (synthetic 8-L-arginine vasopressin; PITRESSIN) is
available as a sterile aqueous solution; it may be administered
subcutaneously, intramuscularly, or intranasally. (2) Desmopressin
acetate (synthetic 1-deamino-8-D-arginine vasopressin; DDAVP,
others) is available as a sterile aqueous solution packaged for
intravenous or subcutaneous injection, in a nasal solution for intranasal
administration  with  either  a  nasal  spray  pump  or  rhinal  tube  delivery
system, and in tablets for oral administration. The therapeutic uses of
vasopressin and its congeners can be divided into two main categories
according to the type of vasopressin receptor involved.
?  Diabetes insipidus - of acute onset and shorter
duration.Vasopressin can be used as an alternative to
desmopressin in the initial diagnostic evaluation of patients with
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suspected  DI  and  to  control  polyuria  in  patients  with  DI  who
recently have undergone surgery or experienced head trauma.
Under these circumstances, polyuria may be transient, and long-
acting agents may produce water intoxication.
Vasopressin-dose – 0.5 to 3U/hr (or)0.01 to 0.04 U/min
- max. safety dose without much CVS compromise
- 0.04U/min or 40mU/kg/hr
- 1U i.v bolus can be given before infusion.
- The pediatric dose range for vasopressin is 0.0003–0.0007
U/kg per minute (0.3–0.7 mU/kg per minute) to a maximum
dose of 2.4 U/h
? Acute GI hemorrhage – V1-receptor-mediated vasoconstriction of
the splanchnic arterial vessels reduces blood flow to the portal
system and thereby attenuates pressure and bleeding in
esophagealvarices. Although endoscopic variceal banding ligation
is the treatment of choice for bleeding esophagealvarices, V1-
receptor agonists have been used in an emergency setting until
endoscopy can be performed.
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Finally, V1-receptor-mediated vasoconstriction has been used to
reduce bleeding during acute hemorrhagic gastritis, burn wound
excision, cyclophosphamide-induced hemorrhagic cystitis, liver
transplant, cesarean section, and uterine myoma resection.
? Vasodilatory shock – resistant to catecholamines(1-5U/hr)
? CPR- 40U single i.v dose may replace first or second dose of
epinephrine.
? Post-op- V1-receptor-mediated contraction of gastrointestinal
smooth muscle has been used to treat postoperative ileus and
abdominal distension and to dispel intestinal gas before
abdominal roentgenography to avoid interfering gas shadows.
? Hemophilia / VWD(desmopressinprefered - 0.3mics/kg)
? Nocturnal enuresis (desmopressinprefered -2.5 mics)
Drug interaction
? POTENTIATION-carbamazepine, chlorpropamide, TCA, opioid,
NSAIDS
? ATTENUATION – demeclocycline, lithium, ethanol.
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? CAUTION- angina, CHF, hypertension
? CONTRAINDICATION- ARF
Adverse effects
Most adverse effects are mediated through the V1 receptor acting
on vascular and gastrointestinal smooth muscle.
? After the injection of large doses of vasopressin, marked facial
pallor owing to cutaneous vasoconstriction is observed
commonly. Increased intestinal activity is likely to cause nausea,
belching, cramps, and an urge to defecate. Most serious, however,
is the effect on the coronary circulation. Vasopressin should be
administered only at low doses and with extreme caution in
individuals suffering from vascular disease, especially coronary
artery disease. Peripheral vasoconstriction and gangrene have
been encountered.
? Coronary vasospasm, arrhythmias, decreased cardiac output.
? The major V2-receptor-mediated adverse effect is water
intoxication, which can occur with desmopressin or vasopressin.
? Urticaria to anaphylaxis- allergic reaction.
REVIEW OF
LITERATURE
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REVIEW OF LITERATURE
The literature was searched and reviewed to seek the supporting
evidences for role of vasopressin in the management of hypernatremiain
braindead patients, effect of traumatic brainstem dysfunction on serum
vasopressin level, effect of, donor hypernatremia on the grafted organs,
the effect of the correction of donor hypernatremia, role of vasopressin
in hemodynamic stability and catecholamine sparing effect of
vasopressin.
1. Charles Ralston, Warwick Butt et al(9)
Study was done on five children with severe brain injury who
developed diabetes insipidus. They received continuous intravenous
treatment with a solution containing both aqueous vasopressin and
appropriate crystalloid replacement. Major manifestations of diabetes
incipidus such as polyuria, hypernatraemia, and decreased urine
osmolalities were corrected in all patients within eight to 28 hours of
treatment.
Diagnostic criteria for diabetes incipidus include polyuria (>30
ml/kg/day), hypernatraemia, and low urine osmolality (<250 mmol/kg).
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Vasopressin infusion was started as soon as the diagnosis of diabetes
insipidus was confirmed.
Vasopressin infusion was started. Crystalloid infusion aimed, to
replace 80-110% of measured urine excretion. The volume replacement
was according to the previous hour's urinary output. Monitoring -
measurement of urine volume every hour, electrolytes every four hours,
and urine osmolality every 12 hours. The serum sodium was recorded
every two to four hours. Therapeutic end point was urine volume <2
ml/kg/hr, urine osmolality >300 mmol/kg, and serum sodium
concentration <145 mmol/l.
Result-in all cases decrease urine output (within 8 hrs) and
decrease in serum sodium were noticed. Average dose ofvasopressin
administered was 9mU/kg/hour (range 5-14 mU/kg/hour).
This report describes, the effective, methods for, the treatment of
diabetes insipidus and the resultant hypernatremia, which include
vasopressin and crystalloid infusions.,
2. Lee YJ, Shen EY, Huang FY, Kao HA, Shyur SD et al(10)
In this study three comatose children with, diabetes insipidus
were treated with in vasopressin infusion. As soon as the diagnosis was
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confirmed Vasopressin infusion was started at a dose of 1.3 to 2.7mU
/kg/hr. Responses monitored were urine flow rate and serum sodium
level. Decrease in urine output was noticed in 1 to 6 hours and decrease
in serum sodium, was noticed 17- 53 hours after the initiation of
treatment. Sodium control was seen during a period of 2.5 to 22 days
until the patients' death, Continuous infusion of vasopressin gave the
advantage of faster onset and shorter duration action. Therefore it could
be easily titrated. They concluded that Vasopressin infusion was a
rational therapy for comatose children with neurogenic diabetes
insipidus.
3. Pennefather et al. (Pennefather SH, Bullock RE, Mantle D,
Dark JH)(11)
It was a prospective study conducted in 24 brain-dead organ
donors. Patients receive either saline or a low dose arginine vasopressin,
infusion after randamization. In the, 11 patients of AVP group, plasma
hyperosmolality reduced (P < 0.05), blood pressure increased (P < 0.01),
inotrope need decreased (P < 0.01), and the, cardiac output was
maintained. In the 13 patients of control group, plasma hyperosmolality
increased (NS); no significant change in other parameters. They,
concluded that the use of a low dose AVP infusion in potential, organ
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donors, reduced, the inotrope requirement, and decreased the sodium
levels in the serum. Target, MAP was between 65-85 mm Hg.
4. Kenneth Katz, Jack Lawler, Jennifer Wax, Robert O'Connor,
Vinay Nadkarn(12)
Vasopressin pressor effects in critically ill children during
evaluation for brain death and organ recovery
They, hypothesized that low dose Vasopressin, infusion during
organ recovery in critically ill children exerted a pressor effect, without
major organ toxicity. Method: 34 VP-treated and 29 age-matched
critically ill controls (C) ?18 years were retrospectively reviewed during
brain death evaluation and organ recovery. Vasopressin dose titrated
clinically to urine output, with high variability. Pressor and inotrope
management was titrated clinically to BP, cerebral perfusion and CVP in
VP and C groups. Outcome measures include dose, type and number of,
pressors and inotropes. Organ function was assessed at recovery and 48
h post-transplant.
Result : VP dose averaged 0.041±0.069 U/kg/h. Average baseline
mean arterial pressure (MAP) before VP infusion was 79±17 mmHg VP
and 76±14 mmHg C. Subsequent average, MAP were: 82±21 mmHg
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after VP infusion versus 71±16 mmHg C and 80±14 mmHg VP versus
68±22 mmHg C. Ability to wean/stop pressors, and inotropes was:
dopamine (14/23) 42% VP versus (10/26) 38% C, epinephrine (4/5)
80% VP versus (0/6) 0% C, norepinephrine / phenylephrine (4/4) 100%
VP  versus  (2/5)  40%  C.  Alpha  agonist  pressor  dependence  was
successfully weaned from 7/9 (78%) VP versus 0/9 (0%) C.
Conclusion : Vasopressin (Low dose vasopressin infusion) treated
patients  were  7.3  times  more  likely  to  wean  from  alpha  agonists  than
comparably managed age matched controls, without adverse affect on
transplant organ function.
5. Figueras et al(13)
They studied deleterious effect of donor hypernatremia on graft
acceptance in OLT.
In the study donor risk factors associated with second OLT (Re
OLT) and graft loss after OLT were evaluated. Total of 649 OLTs in 11
centres during 1992-1993 were analysed. 11 parameters were monitored
including serum sodium level in donor.
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Conclusion:
1. Donor plasma sodium > 155mmol/L was associated with graft
loss within 1 month.
2. Patients with plasma sodium >155mmol/L should be evaluated
carefully before procurement.
6. Eishi Totsuka, Forrest Dodson, Atsushi Urakami, Natalia
Moras, Tomohiro Ishii, Ming-Che Lee, Jorge Gutierrez,
Mauricio Gerardo, Ernesto Molmenti, and John J. Fung(14)
In this study, the effect of hypernatremia on early liver graft
rejection and the effect of its management on outcome during OLT were
evaluated.
181 consecutive OLTs performed between May 1997 and July
1998 were selected for, this study. They divided the patients into, three
groups based on, the donor serum sodium levels.
Group A, serum sodium of 155 mEq/L or less, (n 118); group B,
with peak sodium value greater than 155 mEq/L and final sodium level,
155 mEq/L or less (n, 36); and group C, final sodium level persistently
greater than 155 mEq/L (n 27)., 90 days graft survival, and early
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postoperative graft function after OLT were analyzed. The, observation
was : The frequencies of graft loss were 12.7% in group A, 11.1% in
group B, and 33.3% (P <.05 v groups A and B) in group C.
Conclusion : Elevated liver enzymes and prothrombin, time were
noticed, in the post operative period in group C for 14 days. Incidence of
early graft rejection was higher in hypernatremic group.
7.  Kinoshita  Y,  Yahata  K,  Yoshioka  T,  Onishi  S,  Sugimoto  T
et.al.(15)
In this study 28 braindead patients were divided into 2 groups. 10
patients received epinephrine infusion. In 18 patients Vasopressin
infusion started in addition to epinephrine. 8 out of 10 patients in
epinephrine group went for cardic arrest in < 48 hrs even with higher
doses. Urine output was not controlled. Renal function deteriorated
progressively.
In vasopressin group blood pressure was maintained with low
dose epinephrine. Survival duration was prolonged to 4 days. Urine
output was controlled and RFT normalized. It was concluded that
combined vasopressin and epinephrine infusion maintained normal RFT
for longer time (upto 2 weeks).
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8. Jennifer A. Frontera, Thomas Kalbet al(16).
They explained the role of hormonal therapy in braindead
management. Levothyroxine, solumedrol, Vasopressin and insulin were
used. Hormonal therapy was started when there were hypotension with
features of diabetes insipidus, in braindead patients. In a prospective
study with 19 hemodynamically unstable, braindead patients, refractory
to usual treatment with fluids and inotropes, hormonal therapy was
started and a significant decrease in vasopressor requirement was
noticed.
In another retrospective study with 10292 patients, initiation of
hormonal therapy resulted in high organ yield.
9.  Totsuka E,  Fung U,  Hakamada K,  Tanaka M,  Takahashi  K,
Nakai  M,  Morohashi  S,  Nishimura  A,  Ishizawa  Y,  Ono  H,
Toyoki Y, Narumi S, Sasaki M.(17)
This study was done toto analyse several clinical parameters that
affect 30 day graft loss after, OLT (Orthotopic Liver Transplantation).
186 liver transplantations, that have been done in the period of May
1997 to June 1998 at university of Pittsburgh medical centre, were
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included. Donor variables include age, sex, dopamine dose, cold
ischemia time, warm ischemia time, serum sodium level.
28 grafts were lost. Factors, that affected, the graft survival were
serum sodium> 155 mmol/L, CIT >12 hrs, WIT> 45%.
It was concluded that donor hypernatremia, CIT and WIT
independently affect the graft survival, after OLT. Avoiding long
preservation and correcting serum sodium were suggested to, improve
the graft acceptance.
10. Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu
D, Sakano T, Sugimoto T.(18)
This study was done in 16 braindead patients (14-head injury, 2-
CVA).
10 patients were treated with epinephrine infusion alone with
target systolic BP 90mmHg.Remaining, 6 patients received Vasopressin
infusion at a dose of 1-2U/hr (285+/-45microunits/kg/min), along with
epinephrine infusion.
10 patients treated with epinephrine alone had cardiac arrest
within 48 hrs, with mean survival time 24.1+/-17.2 hrs. In patients who
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received vasopressin infusion the changes noticed were, epinephrine
dose requirement was not more than >0.5mg/hr and prolonged mean
survival time (23.1+/-19.1 days). It was cocluded that in, braindead
patients the role of Vasopressin is critical, in hemodynamic maintenance
and in improving the opportunities for organ transplantation.
11. Luciana Mascia, Ilaria Mastromauro and Silvia
Grottoli etal(19)
Chen et al demonstrated a significant decrease in catecholamine
doses (dopamine/nor epinephrine), using low dose Vasopressin infusion
(0.04-1.0U/min) with considerable increase in MAP and organ
perfusion.They also demonstrated, a complete weaning from
catecholamines in 40% brain-dead patients with the use of Vasopressin.
This  was  supported  by  a  study  done  by  venkateswaran  et  al,  and  they
suggested more extensive vasopressin usage as an alternative to
norepinephrine in the management of brain-dead patients. Also
Yoshioka et al demonstrated a prolonged hemodynamic stability with
combined epinephrine and Vasopressin usage comparing the usage of
epinephrine alone.
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12.  Kerri  M.  Robertson,  MD,  FRCP(C),  and  D.  Ryan  Cook,
MD(20)
It is mentioned that hemodynamic effects of vasopressin are dose-
dependent and include generalized systemic vasoconstriction with an
increase in blood pressure and a decrease in cardiac output, coronary
and renal blood flow, bradycardia, and arrhythmias. With currently
available information, it appears that the benefits of early treatment of
the polyuria of DI with a titratable infusion of vasopressin, thereby
minimizing electrolyte abnormalities, fluid shifts, and a reduction in
core temperature, outweigh the potential for ischemic end-organ injury.
13. V. Shah, G. Bhosale et al(21)
Organ donor problems and their management
In this study they, recommend frequent monitoring of U/O, serum
electrolytes, glucose and urinary electrolytes in this study, when, U/O >
300 ml/hr or 4 ml/kg/hr, desmopress in (1-4 ?g 8-12 hrly), a synthetic
analogue of vasopressin was administered. It has enhanced antidiuretic
potency, greatly diminished pressor activity and prolonged half-life as
compared to Vasopressin. If refractory hypotension is a problem,
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Desmopressinwas, changed to Vasopressin (1 U bolus + infusion 0.5-4
U/hr).
As, polyuria can cause obligatory loss of fluid and electrolytes,
was aggressively managed to maintain haemodynamic and electrolyte
stability. The, previous hour’s U/O, was replaced with a hypotonic fluid
(5% Dextrose in 0.45% NaCl), with close monitoring of electrolytes, as
elevated serum sodium is a risk factor for delayed or primary
nonfunction of grafted organs.
14. Hohenegger M, Vermes M, Mauritz W, Redl G, Sporn P,
Eiselsberg P(22)
Serum vasopressin (AVP) levels in polyuric brain-dead organ
donors.
In this study serum vasopressin level was evaluated in 11
braindead patients. There were polyuria and low urine osmolality
(which was always below the serum osmolality) noticed. Serum
Vasopressin levels of braindead patients were compared with that of the
normal subjects.
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Observation: Serum Vasopressin levels in braindead patients were
between 1.32- 50 pg/ml. In normal subjects the values were between
0.7-8pg/ml.
Conclusion: Thus in this study both normal and elevated Serum
Vasopressin levels were noticed in braindead patients. So the
nephrogenic Diabetes Insipidus was suspected in these patients.
AIM OF THE STUDY
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AIM OF THE STUDY
To evaluate the role of vasopressin in the management of
hypernatremia in clinically brain-dead patients using intravenous
vasopressin infusion at a dose of 0.01-0.04U/min in 40 clinically brain-
dead patients.
MATERIALS
AND
METHOD
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MATERIALS AND METHODS
It  was  a  prospective  a  study  of  evaluation  of  the  role  of
vasopressin in the management of hypernatrmia in clinically braindead
patients, conducted in Government General Hospital, Chennai.
STUDY DESIGN
Prospective, interventional.
After obtaining institutional ethical committee clearance, 40
clinically braindead patients with hypernatremia were selected using
following criteria:
INCLUSION CRITERIA
? Clinically braindead patients (ASA PS 6)
? Traumatic injury
? Serum Na+ level > 145 meq/L
? Urine output > 4ml/kg/hr
EXCLUSION CRITERIA
? Braindead  patients with serum Na+ < 146meq/L
? Urine output < 1.5-2ml/kg/hr
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? Patients with known renal pathology
? Allergy to vasopressin group of drugs
OUTCOME MEASURES
? Serum Na+ level
? Urine output
? Blood pressure
? Serum potassium
? Blood urea
? Serum creatinine
? Pulse rate
? Blood sugar
MONITORING INTERVAL
All parameters were monitored hourly.
Blood pressure- 1st hour – every 15 mins, 2nd & 3rd  hour – every
30 mins, subsequent hours – hourly monitoring (if stable with supports)
for 6 hours.
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MATERIALS
1. 18G venflon
2. Heparin
3. ABG analysis source
4. intra venous fluids (5%D,RL,1/2NS)
5. Monitors- Monitors: ECG, Pulse oximetry, Capnography, NIBP
6. Vasopressin injection
STUDY METHOD
After receiving information from any ward,  patientswere visited
and examined (History and clinical examination) thoroughly.
Investigations were evaluated and if not complete instructions were
given.
After confirming the existence of hypernatremia and verifying
inclusion criteria, consent was obtained from patient’s attenders  and
vasopressin infusion was started at a dose of 0.01U/min or 10mU/kg/hr.
20units vasopressin in 500ml NS  (1ml =0.04U).
Above mentioned parameters were monitored at specified time
intervals for 6 hours.
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RESULTS
1. Serum Na+ reaches the target value
2. Decreased but not to the target level
3. No change in serum Na+ level
4. Persistently increasing levels noted
Interpretation of results
Response to vasoprssin
1. PRESENT- if there was decrease in serum Na+ level (to target
level or decrease >10 to 15% from baseline)
2. NOT- if there was no change or increasing levels.
STATISTICS
Statistical analysis was done to determine the significance
(friedmantest and paired t test were used).
OBSERVATION
AND
RESULTS
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OBSERVATION AND RESULTS
Table: 1
Frequency Table : Demographic Profile - SEX
Sex Frequency Percent
MALE 30 75.0
FEMALE 10 25.0
TOTAL 40 100.0
Male, Female distribution in this study was 75%, 25% respectively.
75%
25%
Male Female
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Table: 2
Frequency Table : MODE OF INJURY
Mode of Injury Frequency Percent
RTA 34 85.0
Fall from Height 6 15.0
Total 40 100.0
In this study 85% cases were road traffic accident, 15% cases
were fall from height.
85%
15%
RTA Fall from height
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Table: 3
Descriptive Statistics : AGE
N Minimum Maximum Mean Std. Deviation
Age in years 40 15 60 33.30 12.041
Mean age was -33.3.
Table: 4
Frequency Table : GCS
GCS Frequency Percent Valid Percent Cumulative Percent
3 40 100.0 100.0 100.0
All the patients had GCS – 3/15
Table:5
ASA
ASA Frequency Percent Valid Percent Cumulative Percent
6 40 100.0 100.0 100.0
All the patients came under ASA-6.
Table: 6
RENAL DISEASE
Renal
Disease Frequency Percent
Valid
Percent
Cumulative
Percent
NIL 40 100.0 100.0 100.0
All the patients were free of any renal pathology.
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Table: 7
Descriptive Statistics, Friedman Test – to compare the hourly values.
SERUM SODIUM
Serum
sodium N Mean
Std.
Deviation Minimum Maximum p-value
Initial 40 160.10 8.041 146 179
<0.001**
1hr 40 158.28 7.582 146 175
2hrs 40 154.77 7.026 142 170
3 hrs 40 151.15 7.145 138 166
4 hrs 40 147.98 7.767 135 166
5 hrs 40 145.12 9.030 132 171
6 hrs 40 142.48 10.195 130 174
There was a consistent decrease in serum sodium level in every hour.
130
135
140
145
150
155
160
165
Initial 1hr 2hrs 3 hrs 4 hrs 5 hrs 6 hrs
160.1
158.28
154.77
151.15
147.98
145.12
142.48
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Table: 8
Paired Samples Statistics
Paired T-Test to compare the initial and final values
Serum
sodium
Mean N
Std.
Deviation
Std. Error
Mean
p - value
Initial 160.10 40 8.041 1.271
< 0.001**
6 hrs 142.48 40 10.195 1.612
There was significant decrease in serum sodium at the end.
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Table: 9
Friedman Test – to compare the hourly values
Urine output
Descriptive Statistics
Urine
output N Mean
Std.
Deviation Minimum Maximum p-value
 Initial 40 240.50 31.861 180 320
<0.001**
 1 hrs 40 222.38 31.297 165 300
 2 hrs 40 205.50 32.715 160 290
 3hrs 40 188.25 33.846 140 290
 4 hrs 40 174.50 35.225 130 280
 5 hrs 40 162.50 38.213 125 290
6 hrs 40 149.88 42.115 110 280
There was a consistent decrease in urine output.
0
50
100
150
200
250
Initial 1hr 2hrs 3 hrs 4 hrs 5 hrs 6 hrs
240.5
222.38
205.5
188.25
174.5
162.5
149.88
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Table: 10
Paired Samples Statistics
Paired T-Test – to compare the initial and final values
Urine
output
Mean N
Std.
Deviation
Std. Error
Mean
p - value
Initial 240.50 40 31.861 5.038
< 0.001**
 6hrs 149.88 40 42.115 6.659
There was significant decrease in urine output at the end.
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Table: 11
Systolic BP Descriptive Statistics
Friedman Test – to compare the hourly values
Systolic
BP N Mean
Std.
Deviation Minimum Maximum p-value
Initial 40 100.32 5.446 90 113
<0.001**
15mins 40 102.23 5.323 92 114
30mins 40 103.98 4.886 94 114
45mins 40 105.58 4.877 96 117
1 hrs 40 105.98 4.938 96 117
1 hrs
30mins 40 108.73 4.883 98 121
2 hrs 40 111.05 4.904 102 123
2 hrs
30mins 40 113.43 4.766 105 125
3 hrs 40 116.07 4.649 107 128
4 hrs 40 121.08 4.376 113 130
5 hrs 40 125.63 4.584 118 135
6 hrs 40 130.05 5.223 122 142
Gradual increase in systolic blood pressure was noticed.
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Table: 12
Paired Samples Statistics
Paired T-Test – to compare the initial and final values
Systolic
BP Mean N
Std.
Deviation
Std. Error
Mean p - value
Initial 100.33 40 5.446 .861
< 0.001**
6 hrs 130.05 40 5.223 .826
There was definite improvement in hemodynamic status.
Table:13
Diastolic BP Descriptive Statistics
Friedman Test – to compare the hourly values
Diastolic
BP N Mean
Std.
Deviation Minimum Maximum p-value
 Initial 40 62.30 4.826 53 75
<0.001**
 15mins 40 63.38 4.839 54 75
 30mins 40 64.68 4.937 55 76
45mins 40 65.50 4.935 57 77
1 hrs 40 66.45 4.878 57 78
 1.30 hrs 40 68.28 4.904 60 78
 2 hrs 40 69.50 5.104 62 80
 2.30 hrs 40 71.70 4.869 65 83
3 hrs 40 73.22 4.605 66 84
 4 hrs 40 76.58 4.701 70 86
 5hrs 40 80.72 4.873 72 90
 6 hrs 40 82.82 4.835 74 92
Gradual increase in diastolic blood was also noticed.
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Table:14
Paired Samples Statistics
Paired T-Test – to compare the initial and final values
Diastolic
BP Mean N
Std.
Deviation
Std. Error
Mean p - value
Initial 62.30 40 4.826 .763
< 0.001**
6hrs 82.83 40 4.835 .765
Table:15
Mean arterial pressure Descriptive Statistics
Friedman Test – to compare the hourly values
Mean
arterial
pressure
N Mean Std.Deviation Minimum Maximum p-value
Initial 40 74.97 4.633 66 88
<0.001**
 15mins 40 77.10 6.515 67 105
 30mins 40 77.70 4.603 68 88
 45mins 40 78.70 4.575 70 90
 1 hrs 40 79.63 4.436 70 91
 1.30 hrs 40 81.68 4.305 73 89
 2 hrs 40 83.33 4.486 75 94
 2.30 hrs 40 85.60 4.301 78 97
 3 hrs 40 87.43 4.069 80 99
 4 hrs 40 91.48 4.309 84 101
 5hrs 40 95.60 4.361 87 104
 6 hrs 40 98.50 4.546 92 108
There was a definite increase in mean arterial pressure at the end
of 6hrs.
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BLOOD PRESSURE VARIATION
0
20
40
60
80
100
120
140
Initial 1 hrs 2 hrs 3 hrs 4 hrs 5 hrs 6 hrs
100.32
105.98
111.05
116.07
121.08
125.63
130.05
62.3 66.45
69.5 73.22
76.58 80.72
82.82
74.97
79.63 83.33
87.43 91.48
95.6 98.5
Systolic Blood Pressure
Diastolic Blood Pressure
Mean Arterial Pressure
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Table: 16
Paired Samples Statistics
Paired T-Test – to compare the initial and final values
Mean arterial
pressure Mean N
Std.
Deviation
Std. Error
Mean p- value
Initial 74.97 40 4.633 .732
< 0.001**
6 hrs 98.50 40 4.546 .719
There was improvement in mean arterial pressure. There was no
significant difference, in serum sodium control, urine output, and blood
pressure control among the male and female population. Mode of injury
didn’t produce any significant difference in sodium control and blood
pressure variation in this study. But significant differences were noticed
in initial and first 3hours post-vasopressin urine output values. Where
higher values were noticed in the fall from height group comparing RTA
group.
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Table : 17
Paired Samples Statistics
Paired T-Test – to compare the initial and final values
Variable Mean N Std.Deviation p-value
Pair 1 Sr.K+ Initial 3.7900 40 .41188
0.635
Sr.K+ Final 3.8450 40 .43908
Pair 2 Sr.creatinine - Initial 1.2075 40 .24744
0.658
Sr.creatinine - Final 1.2250 40 .11929
Pair 3 pulse - Inital 128.95 40 7.56832
< 0.001**
pulse - Final 109.15 40 16.35433
There were no significant changes in serum potassium and serum
creatinine seen in this study. But significant decrease in pulse rate was
noticed. It may be due to the ability to reduce the catecholamine dose
with time - catecholamine sparing effect of vasopressin and improved
volume status.
95
100
105
110
115
120
125
130
Pulse rate Initial Pulse rate Final
128.95
109.15
DISCUSSION
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DISCUSSION
Vasopressin has two major effects in braindead patients,
1. V2 receptor mediated free water retention-which helps to
manage the hypernatremia in braindead patients due to the endocrine
failure that follows posterior pituitary infarction ,which is otherwise
harmful to the potentially transplantable organs, especially when serum
sodium concentration >155mEq/L.(if the diagnosis is confirmed and the
patients relatives give consent for organ donation)
2. V1 receptor mediated vasoconstriction – which helps to
maintain/improve hemodynamic status in braindead patients, who are
usually prone to hemodynamic instability due to the frequently
accompanying autonomic failure.
From  observation  and  statistical  analysis  there  was  almost  a
steady decline in serum sodium in every hour sample with a significant
decrease in sodium level at the end of 6th hour noticed in 31 patients.
Mean initial sodium was 160.10mmol/L and final sodium
concentration was 142.48.mmol/L
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There were consistent decrease in urine output in every hour and
significant decrease in urine output at the end of 6th hour also noticed in
those 31 patients.
Mean initial urine output was 240.50L/hr and final urine output
was 149.88L/hr.
Considerable improvement in blood pressure (in terms of Systolic
Blood pressure, Diastolic Blood pressure, Mean Arterial Pressure) is
also seen in almost all patients.
Mean initial Blood pressure :
Systolic Blood pressure : 100.32mmHg
Diastolic Blood pressure : 62.30mmHg
Mean arterial pressure  : 74.97mmHg
Mean final Blood pressure :
Systolic Blood pressure : 130.05mmHg
Diastolic Blood pressure : 82.82mmHg
Mean arterial pressure : 98.50mmHg
The pathology in these 31 patients could be the central diabetes
insipid us due to posterior pituitary infarction.
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In 9 patients there was no significant decrease in serum sodium
level and urine output, so the pathology in these patients may be
different-could be nephrogenic diabetes insipidus.
Patients selected were cases of traumatic brain death. 2 modes of
injury in these patients were Road traffic accident and fall from height.
distribution was 85%RTA,15% fall from height. There was no
significant difference in these groups of patients regarding drug dosage
or response in serum sodium level or blood pressure or urine output.
Sex distribution: Male-75% Female-25%
There was no significant difference in terms of drug dosage or
response in serum sodium level or blood pressure or urine output due to
sex distribution.
Other parameters monitored include serum potassium, blood urea,
serum creatinine, pulse rate & blood sugar. There were no consistent or
predictable and significant changes noticed in these parameters during
the study.
So vasopressin infusion in clinically brain dead hypernatremic
patients produced,
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1. Significant & definite decrease in serum sodium level
2. Definite decrease in urine output
3. Considerable improvement or stability in haemodynamic status
(Blood pressure), as denoted by decrease in catecholamine
requirement with time.
As explained in review of literaturethese findings are supported
by various studies.
Effect of Vasopressin on serum sodium control is supported by
Charles Ralston, Warwick Butt et al(9) and Lee YJ, Shen EY, Huang FY,
Kao HA, Shyur SD et al.(10)
Catecholamine sparing effect of vasopressin is supported by
Pennefather et al. (Pennefather SH, Bullock RE, Mantle D, Dark JH)(11),
Kenneth Katz, Jack Lawler, Jennifer Wax, Robert O' Connor, Vinay
Nadkarn et al(12), Kinoshita Y, Yahata K, Yoshioka T, Onishi S,
Sugimoto T et al.(15), Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T,
Sadamitsu  D,  Sakano  T,  Sugimoto  T.(18), Luciana Mascia,
IlariaMastromauro and Silvia Grottoli et al(19).
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Desmopressin (DDAVP) is an analog of AVP with a relatively
potent antidiuretic effect and negligible vasopressor activity.
Diabetes insipidus
Central diabetes insipidus - Head injury, either surgical or
traumatic, in the region of the pituitary and/or hypothalamus may cause
central DI. Other causes include hypothalamic or pituitary tumors,
cerebral aneurysms, CNS ischemia, and brain infiltrations and
infections. Finally, central DI may be idiopathic or familial.
Antidiuretic peptides are the primary treatment for central
DI.Vasopressin is preferred for short term uses especially when there is
hypotension. Desmopressin is preferred for long term uses.
Nephrogenic diabetes insipidus - Nephrogenic DI may be
congenital or acquired. Hypercalcemia, hypokalemia, postobstructive
renal failure, lithium, foscarnet, clozapine, demeclocycline, and other
drugs can induce nephrogenic DI. As many as one in three patients
treated with lithium may develop nephrogenic DI. X-linked nephrogenic
DI is caused by mutations in the gene encoding the V2 receptor, which
maps to Xq28. These findings indicate that aquaporin 2 is essential for
the antidiuretic effect of vasopressin in human beings.
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The mainstay of treatment of nephrogenic DI is assurance of an
adequate intake of water. Paradoxically, thiazide diuretics reduce the
polyuria of patients with DI and often are used to treat non-lithium-
induced nephrogenic DI.
SUMMARY
67
SUMMARY
This was a prospective study conducted in 40 clinically braindead
patients with hypernatremia. Trauma patients were chosen.
After confirming hypernatremia with baseline serum sodium
values and inclusion criteria vasopressin infusion was started at a dose
of 0.01U/min.
Hourly serum sodium, serum potassium, urine output, blood urea,
serum creatinine, blood pressure, heart rate and blood sugar were
monitored for 6 hrs.
Blood pressure was monitored – every15 minutes during 1st hour,
every 30 minutes during 2nd & 3rd hour, every hour for next three
hours.
Observed parameters were evaluated for statistical significance.
Statistical analysis was done with appropriate tests.
It shows that the effect of vasopressin in decreasing serum sodium
was statistically significant.
It's effects in decreasing urine output and maintaining
hemodynamic stabily were also significant.
CONCLUSION
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CONCLUSION
As endocrine and autonomic failure both are common in
braindead patients, vasopressin  at a dose of 0.01-0.04U/min will be
superior to other options in managing hypernatremia in these patients as
it handles both hypernatremia and hypotension. Other options
include desmopressin (lacks vasopressor effect) and using sodium free
IV fluids or IVfluids with high free water clearance.
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PROFORMA
PROSPECTIVE STUDY OF EVALUATION OF THE ROLE OF
VASOPRESSIN IN THE MANAGEMENT OF HYPERNATREMIA
IN CLINICALLY BRAINDEAD PATIENTS
NAME : AGE : SEX : I. Po.
DIAGNOSIS:
CASE DETAILS:
HISTORY
MODE OF INJURY & TIME OF INJURY :  CT BRAIN :       TIME OF CLINICAL DECLARATION :
CO-MORBID ILLNESS & TREATMENT DETAILS (INCLUDING JAUNDICE):
EFFORT TOLERANCE _____ METS
ALCOHL INTAKE :
GENERAL EXAMINATION :
HEIGHT : WEIGHT :  EXTERNAL INJURIES/INFECTION :     GCS-
ANAEMIA- JAUNDICE – OEDEMA – CYANOSIS – PUPILS – DEM-
PULSE – BP-SPO2  CVS RS-SPONTANEOUS RESPIRATION –
INVESTIGATIONS :
Hb : BT : CT :     BLOOD GROUPING & TYPING:
BLOOD SUGAR UREA: CREATININE     ELECTROLYTES-Na+k+
ECG  : CXR:
INTERVENTION
BASELINE ABG-Na+
TIME SINCE INJURY
VASOPRESSIN INFUSION – DOSE (01.1-0.04 U/min)
STARTING TIME
PARAMETERS TO BE OBSERVED
1. SERUM Na+LEVEL
2. SERUM K+
3. URINE OUTPUT
4. BLOOD UREA
5. SERUM CREATININE
6. PULSE RATE
7. BLOOD PRESSURE
8. BLOOD SUGAR
TIME TAKEN TO ATTAIN (FROM INFUSION) SERUM Na+ (146meq/L)
TIME Na+ K+ UO UREA CREATININE PR BP SUGAR
LOOK FOR ADVERSE EFFECTS
Sl.No. Name AGE SEX IPNO MODE GCS ASA RENALDISEASE Sr.Na+ INITIAL 1st hr 2nd hr 3rd hr 4th hr 5th hr 6th hr U.O INITIAL 1st hr 2nd hr 3rd hr 4th hr
1 Indhra 28 F 74175 RTA 3 6 NIL 158 156 152 148 146 142 140 250 235 210 190 185
2 Shanthakumari 60 F 75615 RTA 3 6 NIL 159 156 150 146 141 138 134 220 200 175 160 150
3 Ravi kumar 31 M 51756 RTA 3 6 NIL 174 173 170 166 166 168 166 250 250 240 235 225
4 Kasinathan 50 M 57617 RTA 3 6 NIL 160 157 151 145 140 137 133 225 210 190 180 165
5 Madhumitha 18 F 42698 RTA 3 6 NIL 146 150 156 162 166 171 174 230 230 225 220 210
6 Prabhakaran 22 M 46773 FALL 3 6 NIL 164 162 158 153 148 142 138 300 275 260 220 185
7 Desingh 32 M 89269 RTA 3 6 NIL 156 153 148 145 142 137 133 200 185 165 150 140
8 Sandiyappan 57 M 87170 RTA 3 6 NIL 153 150 145 142 140 138 134 180 165 160 150 135
9 Malliga 34 F 22707 RTA 3 6 NIL 170 167 163 159 155 150 146 240 220 200 185 175
10 Kannan 39 M 23805 RTA 3 6 NIL 159 157 153 151 146 143 138 280 265 240 220 195
11 Iakshmi 45 F 27543 RTA 3 6 NIL 150 147 145 142 140 137 135 320 300 275 240 210
12 Perumal 30 M 29884 RTA 3 6 NIL 155 154 150 146 142 139 136 200 185 160 150 140
13 Kali 23 M 61103 RTA 3 6 NIL 158 157 155 153 152 152 152 220 210 200 190 200
14 Devi 18 F 61684 RTA 3 6 NIL 177 172 165 157 150 146 140 250 230 215 190 170
15 Kumaran 42 M 62213 RTA 3 6 NIL 154 153 150 146 143 141 138 275 250 220 180 170
16 Shankar 38 M 63215 RTA 3 6 NIL 152 150 146 142 140 138 137 230 210 195 185 170
17 Jagan 20 M 65589 RTA 3 6 NIL 168 167 165 162 164 162 162 240 230 230 220 230
18 Arun 22 M 10415 FALL 3 6 NIL 151 148 146 143 141 137 135 220 220 195 170 150
19 Chandrayan 42 M 11063 RTA 3 6 NIL 157 157 155 153 152 152 150 250 240 240 230 230
20 Fathima 55 F 14026 RTA 3 6 NIL 161 159 156 152 148 145 143 225 200 180 165 145
21 Ashok kumar 30 M 18019 RTA 3 6 NIL 160 160 156 151 146 142 139 240 215 200 175 160
22 Sathish 25 M 19732 FALL 3 6 NIL 156 153 148 144 141 138 136 225 210 180 155 150
23 Basheer 28 M 21790 RTA 3 6 NIL 163 162 156 152 146 140 137 240 220 195 175 150
24 Jagadhesh 27 M 24026 FALL 3 6 NIL 147 148 150 151 151 153 154 320 300 290 290 280
Sl.No. Name AGE SEX IPNO MODE GCS ASA RENALDISEASE Sr.Na+ INITIAL 1st hr 2nd hr 3rd hr 4th hr 5th hr 6th hr U.O INITIAL 1st hr 2nd hr 3rd hr 4th hr
25 Kumari 55 F 27140 FALL 3 6 NIL 168 165 160 154 148 145 138 300 280 265 240 200
26 Rambabu 18 M 35488 RTA 3 6 NIL 152 150 146 142 140 137 133 240 210 195 170 150
27 Manic basha 45 M 36835 RTA 3 6 NIL 166 16 165 163 161 160 160 230 220 230 240 220
28 Suresh 32 M 38931 RTA 3 6 NIL 152 150 147 142 138 133 130 190 175 160 140 130
29 Syed ahamed 45 M 40132 RTA 3 6 NIL 155 154 150 146 143 141 139 250 220 190 175 150
30 Rajaul 22 M 42328 RTA 3 6 NIL 163 160 155 151 146 143 141 230 210 185 160 145
31 Ramya 15 F 44636 RTA 3 6 NIL 167 165 160 154 149 145 142 220 190 170 150 140
32 Gurulingam 48 M 45938 RTA 3 6 NIL 165 165 163 164 160 158 158 210 200 210 210 200
33 Manikandan 21 M 47344 FALL 3 6 NIL 149 146 142 138 135 132 130 280 250 225 210 190
34 Manikandan 19 M 50149 RTA 3 6 NIL 179 175 167 160 154 146 140 240 220 200 175 155
35 Babu 32 M 54328 RTA 3 6 NIL 172 170 165 161 156 152 147 220 195 175 160 145
36 Saraswathi 35 F 72893 RTA 3 6 NIL 154 154 156 154 155 153 153 250 240 240 220 240
37 Jaihalaudin 31 M 73322 RTA 3 6 NIL 159 156 152 148 145 142 140 220 190 170 155 140
38 Pari 39 M 32398 RTA 3 6 NIL 166 164 159 153 148 145 142 220 200 175 160 155
39 Ramesh 29 M 34426 RTA 3 6 NIL 165 162 157 151 146 140 137 230 200 190 165 150
40 Vatsalan 30 M 29466 RTA 3 6 NIL 164 162 158 154 149 145 139 260 240 200 175 150
5th hr 6th hr BP initialSBP DBP MAP
15min
SBP DBP MAP
30min
SBP DBP MAP
45min
SBP DBP MAP 1hr SBP DBP MAP
1hr30
min SBP DBP MAP
2hrs
SBP DBP MAP
2hrs
30mins
SBP
DBP
180 170 96 62 73 98 63 75 99 65 76 100 64 76 100 66 77 104 67 79 106 68 81 107 71
140 125 102 64 77 105 64 78 106 65 79 106 66 79 108 66 80 110 69 83 111 69 83 115 73
220 220 92 65 74 94 66 75 98 67 77 102 68 79 100 68 79 104 71 82 106 72 83 110 74
155 140 106 70 82 108 72 84 108 75 86 111 76 88 111 77 88 113 77 89 115 76 89 118 79
200 210 113 75 88 114 75 88 112 76 88 117 77 90 117 78 91 121 78 89 123 80 94 125 83
160 140 104 67 79 104 68 80 108 70 83 108 71 83 110 73 85 111 76 88 114 78 90 117 81
135 120 102 68 79 105 69 81 108 71 83 108 70 83 107 70 82 112 74 87 116 76 89 116 75
130 120 110 72 85 112 73 86 114 72 86 116 73 87 116 74 88 118 75 89 121 77 92 124 78
160 140 101 65 77 102 67 79 105 68 80 105 70 82 106 71 83 108 73 85 109 73 85 111 73
175 140 94 65 75 97 66 76 99 67 78 101 68 79 100 68 79 103 70 81 105 72 83 108 74
170 130 98 62 74 98 61 73 101 64 76 104 65 78 105 67 80 108 69 82 111 72 85 115 76
125 120 103 68 80 106 70 82 108 73 85 109 75 86 109 75 86 111 77 88 114 79 91 116 80
200 200 104 66 79 106 66 79 108 68 81 110 67 81 111 69 83 114 71 85 116 71 86 118 72
155 145 94 58 70 95 58 70 97 59 72 100 59 73 102 61 75 105 63 77 108 63 78 111 65
160 150 99 65 76 102 66 78 104 67 79 106 69 81 104 70 81 108 73 85 107 74 85 110 77
150 130 90 55 67 92 55 67 96 57 70 96 58 71 97 59 72 100 60 73 102 63 76 106 65
220 220 98 60 73 101 61 74 102 62 75 103 62 76 105 65 78 110 66 81 114 68 83 117 72
140 130 96 62 73 98 63 78 100 64 76 101 64 76 103 66 78 105 68 80 108 69 82 110 72
235 230 102 59 73 105 61 105 106 62 77 108 64 79 109 64 79 111 64 80 113 62 799 116 65
125 110 100 58 72 102 59 73 104 61 75 105 62 76 105 63 77 109 65 80 112 67 82 115 68
140 130 95 60 72 98 61 73 100 63 75 102 64 77 101 65 77 104 68 80 105 72 83 108 75
140 135 104 66 79 105 66 79 107 68 81 108 69 82 108 69 82 110 70 83 112 72 85 114 73
145 125 100 63 75 102 64 77 103 65 78 103 66 78 104 68 80 105 69 81 107 70 82 110 72
290 280 96 57 70 99 59 72 100 60 73 102 61 75 103 61 75 106 63 77 108 64 79 111 66
5th hr 6th hr BP initialSBP DBP MAP
15min
SBP DBP MAP
30min
SBP DBP MAP
45min
SBP DBP MAP 1hr SBP DBP MAP
1hr30
min SBP DBP MAP
2hrs
SBP DBP MAP
2hrs
30mins
SBP
DBP
175 140 105 68 80 107 69 82 108 70 83 111 71 84 110 71 84 112 73 86 114 73 87 115 75
140 120 90 56 67 93 57 69 95 58 70 97 60 72 98 61 73 102 62 75 104 64 77 107 67
220 210 96 60 72 98 60 73 100 61 74 102 62 75 102 63 76 105 65 78 109 66 80 110 68
125 110 106 58 74 107 59 75 109 60 76 110 60 76 111 61 78 113 64 80 115 65 82 117 66
130 120 103 60 74 105 62 76 107 63 78 106 64 78 107 64 78 108 67 81 111 66 81 113 67
140 125 98 56 70 100 57 71 101 58 72 103 60 74 103 61 75 106 63 77 107 64 78 106 66
130 125 104 58 73 104 59 74 106 61 76 107 62 74 108 64 79 110 63 79 113 62 79 115 67
190 190 106 62 77 109 64 79 111 65 80 112 66 81 112 67 82 115 68 84 116 71 86 118 73
165 140 98 58 71 99 60 73 100 60 73 103 61 75 104 61 75 106 63 77 109 65 80 111 68
140 130 102 64 77 104 65 78 107 66 80 108 67 81 108 68 81 111 70 84 115 70 85 117 72
130 120 92 53 66 92 54 67 94 55 68 97 57 70 96 57 70 98 60 73 102 62 75 105 65
230 230 108 66 80 109 68 82 109 69 82 110 70 83 111 70 84 114 74 87 115 76 89 116 77
130 110 94 61 72 97 63 74 99 64 76 100 64 76 100 65 77 102 66 78 105 68 80 108 70
140 125 105 58 74 105 60 75 106 60 75 108 61 77 109 61 77 110 62 78 112 62 79 114 66
135 120 102 60 74 105 61 76 106 63 77 108 62 77 108 64 79 112 67 82 115 69 84 118 70
130 120 105 62 76 107 64 78 108 65 79 110 65 80 111 67 82 115 68 84 117 70 86 119 72
MAP 3hrsSBP DBP MAP
4hrs
SBP DBP MAP
5hrs
SBP DBP MAP
6hrs
SBP DBP MAP Sr.K+ Initial final
Sr.
creat-
inine
initial final pulse initial final
83 110 76 87 118 75 89 126 81 96 132 86 101 4.2 3.4 1.3 1.2 148 114
87 117 75 89 121 74 90 124 75 91 126 78 94 3.8 3.6 1.8 1.3 134 118
86 115 75 88 126 80 95 135 83 100 142 85 104 3.5 4.6 1.1 1.2 138 112
92 122 80 94 127 84 98 132 89 103 136 92 107 4 3.2 1.4 1.2 130 122
97 128 84 99 130 86 101 133 87 102 134 89 104 3.2 3.6 1.3 1.4 124 108
93 121 82 95 126 86 99 133 90 104 138 92 108 4.5 3.8 1.4 1 130 114
89 117 74 88 120 77 91 122 80 94 124 82 96 3.1 4.2 1.6 1.4 125 118
93 125 79 94 128 81 97 133 84 100 138 86 103 3.3 4.6 1.2 1.3 118 110
86 114 71 85 119 72 88 123 73 90 126 75 92 4.2 3.8 1.4 1.1 124 116
85 111 75 87 117 77 90 120 84 96 122 82 95 4 3.5 1.2 1.1 146 122
89 117 80 92 122 86 98 128 88 101 132 90 104 3.6 4 1.1 1.5 136 118
92 118 80 93 123 82 95 126 84 98 138 85 103 3.8 3.4 1.3 1.1 128 106
87 120 70 87 125 76 92 128 80 96 130 84 99 4.2 3.8 1.6 1.2 126 114
80 113 67 82 119 72 88 123 78 93 128 76 93 4 3.4 1.1 1.2 128 116
88 114 78 90 121 84 96 128 82 97 134 86 102 3.6 4.8 1.6 1.4 134 112
79 110 68 82 118 75 89 123 78 93 128 76 93 3.2 4 1 1.2 142 118
87 119 74 87 124 80 95 128 86 100 132 84 100 3.6 3.8 1.2 1.3 130 116
85 114 76 89 119 75 90 123 80 94 128 83 98 2.9 3.6 1.1 1.2 124 106
82 118 68 85 123 70 88 130 85 100 133 84 100 3.6 4.4 1.3 1 130 108
84 116 70 85 122 76 91 126 80 95 128 82 97 4.2 3.4 1.3 1.1 124 112
86 110 76 87 116 70 85 123 88 100 127 86 100 3.8 4.2 1 1.2 120 104
87 115 74 88 117 73 88 120 77 91 125 79 94 3.4 4 0.9 1.1 128 116
85 112 73 86 115 77 90 119 82 94 124 86 99 3.6 3.8 1.1 1.3 122 108
81 115 68 84 119 74 89 122 76 91 130 78 95 4 3.4 1 1.2 142 118
MAP 3hrsSBP DBP MAP
4hrs
SBP DBP MAP
5hrs
SBP DBP MAP
6hrs
SBP DBP MAP Sr.K+ Initial final
Sr.
creat-
inine
initial final pulse initial final
88 117 74 88 121 78 92 124 82 96 126 80 95 4.8 3.6 1.7 1.3 132 14
80 110 68 82 115 70 85 119 73 88 122 78 93 3.9 4.6 1.2 1.4 127 106
82 114 70 85 121 74 90 126 77 93 131 79 96 4 3.4 0.9 1.1 118 104
83 121 68 86 128 75 96 130 78 95 132 81 98 4.2 3.2 1 1.2 134 112
82 115 69 84 118 71 87 122 74 90 126 78 94 3 4.4 1.2 1.3 124 106
79 110 68 82 115 72 86 119 78 92 124 81 99 4 3.8 1.5 1.3 126 108
83 119 68 85 122 75 91 126 73 91 128 74 92 4.2 3.6 1.2 1.4 118 104
88 121 75 90 127 80 96 130 86 101 138 92 107 3.4 4.1 1.2 1.1 120 106
82 113 70 84 117 74 88 123 79 94 127 82 97 3.8 4 1.2 1.3 136 114
87 120 74 89 126 79 95 133 83 100 140 86 101 3.6 4.4 1.4 1.2 128 116
78 107 66 80 113 70 84 118 72 87 123 77 92 3.8 4.4 0.9 1.2 122 104
90 118 78 91 123 81 95 127 84 98 132 86 101 4.2 3.5 1.1 1.3 126 108
83 109 72 84 114 75 88 121 80 94 127 84 98 4.2 3.8 1.1 1.2 132 114
82 116 68 84 118 70 86 122 73 89 125 76 92 3.8 3.2 0.8 1 126 106
86 120 73 89 124 78 93 129 83 98 134 88 103 3.6 4.1 0.7 1.2 120 102
88 122 75 91 126 79 95 128 84 99 132 85 101 3.8 3.4 0.9 1.3 138 116
Prospective study of evaluation of the role of vasopressin in the 
management of hypernatremia in clinically brain dead patients. 
KEY WORDS 
Braindeath , diabetes insipidus  , increased urine output , hypernatremia, graft 
rejection , vasopressin  infusion, serum sodium control. 
ABSTRACT 
    After the diagnosis of  brain death the focus of patient care shifts from 
interventions aimed at  saving  the patients  life to interventions aimed at 
maintaining  viability of potentially transplantable organs. A number of 
physiological changes occur in braindead patients – two important notable features 
are  autonomic nervous system failure  with hypotension and endocrine failure ,due 
to ischemic damage involving hypothalamus &pituitary damage . Most common 
endocrine abnormality is diabetes insipidus. It is  characterized by – serum 
hyperosmolarity , hypernatremia , excessive urine output, low urine osmolarity and  
specific gravity .In braindead patients  incidence of  hypotension  and   
hypernatremia are  81%  and  75-77% respectively. Dis  advantages of donor 
hypernatremia include increased graft loss - especially liver (when 
sr.Na+>155meq/L, due to formation of   idiogenic osmoles )  , prolonged 
prothrombin time in the post op period , prolonged  ICU stay and  may reduce 
patient survival. Duration of hypernatremia  also influences the graft survival.  So, 
maintaining  serum  sodium  level within normal limits may improve  graft 
outcome (especially liver ).It is supported by various studies.  In this prospective 
interventional  study vasopressin infusion was used in 40 clinically braindead 
patients with hypernatremia(sr.Na+> 145 meq/L)  and U.O >2ml/kg/hr(diabetes 
incipidus) , to treat  hypernatremia . Target serum sodium was < 146 meq/L or 
atleast <155meq/L when initial  level was too high. Vasopressin  infusion - dose – 
0.5 to 3U/hr  ( or) 0.01 to 0.04 U/min(10-40  mU/kg/hr) i.v. Decrease in serum  
sodium levels and decrease in urine output were  seen in 31 patients. In 9 patients 
there was no significant change in serum sodium level.  There was also 
considerable improvement in hemodynamic status noticed in these patients. 
Statistical analysis showed that  the  changes in serum sodium  level , urine output 
and hemodynamic status were significant. 
 
 
 
 
 
